Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. The Company uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Its primarily focused on cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. The Company operates through the research and development of de novo protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. The Company’s primary areas of focus are on oncology, inflammation, and autoimmunity. Its de novo protein design process uses a set of advanced computational algorithms and methods to design functional de novo proteins.
NLTX - Neoleukin Therapeutics Inc
Report
There was a problem reporting this post.
Block Member?
Please confirm you want to block this member.
You will no longer be able to:
See blocked member's posts
Mention this member in posts
Please allow a few minutes for this process to complete.